Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,163.65INR
10:21am GMT
Change (% chg)

Rs11.65 (+0.54%)
Prev Close
Rs2,152.00
Open
Rs2,155.00
Day's High
Rs2,196.50
Day's Low
Rs2,144.20
Volume
669,025
Avg. Vol
565,873
52-wk High
Rs2,948.80
52-wk Low
Rs1,901.15

Select another date:

Mon, Feb 19 2018

BRIEF-Dr.Reddy's Laboratories Says Amended Complaint w.r.t U.S. Class Action Lawsuit Filed

* W.R.T U.S. CLASS ACTION LAWSUIT, AMENDED COMPLAINT FILED BY PLAINTIFF WHERE CHAIRMAN, COO AND U.S. UNIT ADDED AS DEFENDANTS Source text - http://bit.ly/2CvdcnN Further company coverage:

BRIEF-Dr.Reddy's Lab Announces Launch Of Tetrabenazine Tablets In U.S. Market

* SAYS ANNOUNCEMENT OF LAUNCH OF TETRABENAZINE TABLETS IN U.S. MARKET Source text - http://bit.ly/2GH4t5d Further company coverage:

India's Dr. Reddy's third-quarter profit tumbles, hit by U.S. pricing pressure

Indian generic drugmaker Dr. Reddy's Laboratories Ltd said quarterly net profit slumped nearly 40 percent, its third consecutive quarter of declines as pricing pressures in the United States hit sales.

UPDATE 1-India's Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure

* Europe generics revenue down 7 pct (Adds revenue drops for N. American, European generics business)

BRIEF-India's Dr.Reddy's Laboratories Dec-Qtr Consol Net PAT Falls 38.5 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.03 BILLION RUPEES VERSUS PROFIT OF 4.92 BILLION RUPEES LAST YEAR

BRIEF-Dr.Reddy's Laboratories Launches Melphalan Hydrochloride Injection In U.S.

* SAYS LAUNCH OF MELPHALAN HYDROCHLORIDE FOR INJECTION IN U.S. MARKET Source text - http://bit.ly/2C8souU Further company coverage:

BRIEF-Dr. Reddy's Reaches Settlement With U.S. Government Regarding Compliance With Consumer Product Safety Act

* DR. REDDY'S ANNOUNCES IT HAS REACHED A SETTLEMENT WITH US GOVERNMENT REGARDING COMPANY'S COMPLIANCE WITH CONSUMER PRODUCT SAFETY ACT

BRIEF-Dr.Reddy's Labs Gets EIR From U.S. FDA ‍​For Facility In Hyderabad

* SAYS GETS EIR FROM U.S. FDA ‍​FOR CUSTOM PHARMA SERVICES FACILITY IN HYDERABAD Source text - http://bit.ly/2ANfrXj Further company coverage:

BRIEF-Dr.Reddy's Labs Gets U.S. FDA Nod For Psoriasis Treatment

* SAYS CO, THROUGH UNIT, GETS NDA NOD FOR PSORIASIS TREATMENT Source text: http://bit.ly/2kd95cA Further company coverage:

BRIEF-Dr.Reddy's Laboratories gets German Regulator's Nod For CAPA Plan

* SAYS GERMAN REGULATOR PERMITTED PRODUCTION TO START AGAIN FROM FACILITY FOR EU MARKET‍​

Select another date: